Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4787-4793

  Qu, Shimian ^a   Long, Jirong ^a   Cai, Qiuyin ^a   Shu, Xiao Ou ^a   Cai, Hui ^a   Gao, Yu Tang ^b   Zheng, Wei ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b SHANGHAI CANCER INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; NUCLEAR PROTEIN; NME1 PROTEIN, HUMAN; NUCLEOSIDE DIPHOSPHATE KINASE NM23;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHEMICAL ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DNA PROTEIN COMPLEX; FOLLOW UP; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; METASTASIS; NME1 GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DNA INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; ALLELE; BIOSYNTHESIS; BREAST TUMOR; COHORT ANALYSIS; FEMALE; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROMOTER REGION; TREATMENT OUTCOME;

ADULT; ALLELES; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TREATMENT OUTCOME;

EID: 51049124515     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0083     Document Type: Article

References (23)

1. Liotta LA, Stetler-Stevenson WG. Principles of molecular cell biology of cancer: cancer metastasis. In: DeVita SHV, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott Co.; 1993. p. 134-49.
2. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4.
3. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
4. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007;369: 1742-57.
5. Palmieri D, Horak CE, Lee JH, Halverson DO, Steeg PS. Translational approaches using metastasis suppressor genes. J Bioenerg Biomembr 2006;38:151-61.
6. Leone A, Flatow U, King CR, et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991;65:25-35.
7. Leone A, Flatow U, Van Houtte K, Steeg PS. Transfection of human nm23-1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity. Oncogene 1993;8:2325-33.
8. Ouatas T, Salerno M, Palmieri D, Steeg PS. Basic and translational advances in cancer metastasis: Nm23. J Bioenerg Biomembr 2003;35:73-9.
9. Boissan M, Wendum D, Arnaud-Dabernat S, et al. Increased lung metastasis in transgenic NM23-Null/SV40 mice with hepatocellular carcinoma. J Natl Cancer Inst 2005;97:836-45.
10. Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 2000;87:295-300.
11. Lu H, Shu XO, Cui Y, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005;65:5015-9.
12. Shu XO, Gao YT, Cai Q, et al. Genetic polymorphisms in the TGF-β1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study-Cancer Res 2004;64:836-9.
13. Horak CE, Lee JH, Elkahloun AG, et al. Nm23-1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res 2007;67:7238-46.
14. Hunter KW, Crawford NP. Germ line polymorphism in metastatic progression. Cancer Res 2006;66: 1251-4.
15. Rubio SA, Martinez SE, Corona JS, et al. Eco Rl polymorphism of the metastasis-suppressor gene NME1 in Mexican patients with breast cancer. Breast Cancer Res Treat 2006;96:159-61.
16. Ouatas T, Clare SE, Hartsough MT, De La RA, Steeg PS. MMTV-associated transcription factor binding sites increase nm23-1 metastasis suppressor gene expression in human breast carcinoma cell lines. Clin Exp Metastasis 2002;19:35-42.
17. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005;16: 1723-39.
18. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96: 1504-13.
19. Hayes DF. Prognostic and predictive factors revisited. Breast 2005;14:493-9.
20. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
21. van't Veer LJ, Dai H, van d Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
22. Park YG, Zhao X, Lesueur F, et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005;37:1055-62.
23. Yang H, Crawford N, Lukes L, Finney R, Lancaster M, Hunter KW. Metastasis predictive signature profiles pre-exist in normal tissues. Clin Exp Metastasis 2005; 22:593-603.